Spanish biopharma company PharmaMar reported that its Plitidepsin drug has a “potent preclinical efficacy” against COVID-19. Referencing a peer-reviewed paper published in the journal Science, the company reported that the drug led to a 99% reduction in viral loads in the lungs of animals treated with Plitidepsin. The study’s authors wrote: “We believe that our data and initial positive results from PharmaMar’s clinical trial suggests that Plitidepsin should be strongly considered for expanded clinical trials for the treatment of COVID-19.”
Give the gift of hope
We practice what we preach:
accurate, fearless journalism. But we can't do it alone.
- On the ground in Gaza, Syria, Israel, Egypt, Pakistan, and more
- Our program trained more than 100 journalists
- Calling out fake news and reporting real facts
- On the ground in Gaza, Syria, Israel, Egypt, Pakistan, and more
- Our program trained more than 100 journalists
- Calling out fake news and reporting real facts
Join us.
Support The Media Line. Save democracy.
